In the age of weight-loss drugs like Ozempic and Wegovy, major food companies are adding new products to their lineups, The ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Buying an air conditioner can be daunting, especially with so many brands, features and specifications to choose from. HVAC brands, such as Lennox and Carrier focus primarily on comfort features ...

CHRISTMAS is famously a period of indulgences and there’s nothing wrong with partaking in a mince pie or roast with all the ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity medications. But it's not clear if the proposed change will go into effect.

The six new names and colours of the London Overground lines have been officially launched by the Mayor of London. The rebrand aims to celebrate "untold elements of London's cultural history" with ...

The company sees this as promising, stating that this patient population “typically lose(s) less weight on GLP-1 therapies.” Moreover, the average hemoglobin A1C (HbA1c) was also lowered by up to 2.2 ...

All did not go to plan on his debut, though, as they lost 1-0 to Everton - and we want to know if you can name the Toffees team from that day ahead of the two sides crossing paths this weekend.

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), ...

receiving GLP-1 RA treatment. Among these, only 286 participants were part of randomised controlled trials (RCT). RCT data provided mixed results. Treatment with exenatide over 24 weeks did not ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed ...